Oracle and Eli Lilly Flag as Deeply Undervalued in GF Value Scan as Forward Industries Signals Speculative Excess

The Quick Take

• Oracle (ORCL) and Eli Lilly (LLY) show 22.6% and 25.1% undervaluation on GF Value respectively, with Eli Lilly's oral GLP-1 now reaching one-third of new patients
• Forward Industries (FWDI) flagged at 5,735% overvaluation after massively expanding its Solana treasury holdings in a MicroStrategy-style crypto pivot
• American Airlines (AAL) faces FAA-mandated flight suspensions at Philadelphia and Newark, adding operational disruption to already challenging macro headwinds

A broad GF Value screening across 18 stocks on September 21 revealed a market divided between genuinely undervalued quality names and speculative outliers commanding extreme premiums. Oracle edged higher to $148.50 amid subdued options activity, while Eli Lilly CEO Dave Ricks confirmed on CNBC that approximately one-third of new patients are starting treatment with the company's oral GLP-1 formulation — a development that materially improves the addressable market for its obesity and diabetes franchise. Both companies trade at substantial discounts to their GF Value intrinsic estimates of 22.6% and 25.1% respectively, suggesting the market is underappreciating their earnings durability.

At the speculative extreme, Forward Industries registered a 5,735% overvaluation reading after announcing an aggressive expansion of its Solana treasury holdings — a strategy echoing MicroStrategy's Bitcoin accumulation playbook but applied to an altcoin with considerably higher volatility and weaker institutional adoption. The discrepancy between FWDI's underlying business fundamentals and its implied valuation from crypto treasury holdings creates significant risk for momentum-driven shareholders. American Airlines presented a different type of risk: FAA-mandated temporary suspensions of incoming flights at Philadelphia, Newark, and other key hubs created near-term operational disruptions that suppressed the stock even as the broader market advanced strongly.

The breadth of the GF Value scan across sectors — from healthcare and enterprise software to airlines and crypto-adjacent equities — illustrates the increasingly fragmented nature of the current market environment. Quality value names in established sectors trade at meaningful discounts while speculative treasury-strategy plays command premium valuations disconnected from operating fundamentals. H.C. Wainwright maintained neutral on Alkermes following promising clinical findings, suggesting even positive clinical data does not automatically translate to valuation upgrades in biotech. For active stock pickers, the session offered both compelling long opportunities in neglected quality names and cautionary signals against chasing crypto-treasury-conversion trades without underlying business justification.

Synthesized from 18 sources.